Parkinson's disease psychosis (PDP) is a common and often very disturbing 
component of Parkinson's disease (PD). PDP consists of hallucinations that are 
mainly visual and delusions that are often of a paranoid nature. These symptoms 
can be the most troubling and disruptive of all the manifestations of 
Parkinson's disease. Current treatment methods include the reduction of 
anti-Parkinson's medications, a strategy that may worsen the motor problems the 
medications are prescribed to alleviate, and the introduction of selected 
antipsychotic medications that carry with them the potential for troubling side 
effects and serious consequences. Pimavanserin has been developed and studied in 
clinical trials to specifically address Parkinson's disease psychosis and has 
been submitted to the U.S. Food and Drug Administration for its approval for 
this purpose. If this is granted, we believe the evidence of Pimavanserin 
efficacy, safety and tolerability will position this medication as the first 
choice for treatment of Parkinson's disease psychosis.